Trial of Lixisenatide in Early Parkinson’s Disease
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease. METHODS: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary end point was the change from baseline in scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent. RESULTS: A total of 156 persons were enrolled, with 78 assigned to each group. MDS-UPDRS part III scores at baseline were approximately 15 in both groups. At 12 months, scores on the MDS-UPDRS part III had changed by -0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P = 0.007). At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary end points did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%. CONCLUSIONS: In participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease. (Funded by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov number, NCT03439943.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Three clinical trials consistently describe a slowed decline in motor function when using the short-acting GLP-1 receptor agonists exenatide and lixisenatide in people with Parkinson's disease; 102-104”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [104]
In the citing paper
“The results showed that liraglutide had a modest positive effect on improving motor function and performed well in terms of safety and tolerability, although there were some manageable gastrointestinal side effects.432”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [432]
In the citing paper
“Treatment with exenatide or lixisenatide for 1 year produced a modest but positive effect on Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores in people with recently diagnosed Parkinson’s disease (15, 53).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [53]
In the citing paper
“In Parkinson's disease, phase II trials have shown that GLP-1 RAs such as exenatide and lixisenatide improve motor activity compared to placebo,53,54 and liraglutide has shown improvements in non-motor symptoms, mobility, and quality of life.55”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [54]
In the citing paper
“In addition, lixisenatide slowed motor decline in a phase 2 randomized clinical trial in patients with early Parkinson disease.33”
From Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity (2025) · cites this paper as [33]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
Self-citationSystematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
JENKINSON, C., FITZPATRICK, R., PETO, V., GREENHALL, R., & HYMAN, N. (1997) · Age and Ageing · doi:10.1093/ageing/26.5.353 · Cited by 1,321
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G.-L., Widner, H., Mari�, R.-M., R�my, P., Levivier, M., & Conference Participants: Conference Participants: G. L. Defer, M. (. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4<572::aid-mds1005>3.0.co;2-c · Cited by 865
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Self-citationTrial of Prasinezumab in Early-Stage Parkinson’s Disease
Pagano, G., Taylor, K. I., Anzures-Cabrera, J., Marchesi, M., Simuni, T., Marek, K., Postuma, R. B., Pavese, N., Stocchi, F., Azulay, J.-P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202867 · Cited by 421
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“432 The study emphasizes the need for further research into the potential bene fi ts and risks of liraglutide in patients at different stages of PD. 432 GLP-1RAs and addictive disorders .”
BackgroundTanner, C. M., & Ostrem, J. L. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2401857 · Cited by 382
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“Positive results, principally the halting of disease progression, were reported in trials of exenatide twice daily 136 , exenatide once weekly 137 and lixisenatide once daily 138 .”
Parkinson disease therapy: current strategies and future research priorities
Stocchi, F., Bravi, D., Emmi, A., & Antonini, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01034-x · Cited by 204
“For example, glucagon-like peptide 1 receptor agonists that are used to treat diabetes have shown promise in patients with PD, highlighting a potential role for brain insulin signalling and insulin receptors in this condition 133,134 .”
Vijiaratnam, N., Girges, C., Auld, G., McComish, R., King, A., Skene, S. S., Hibbert, S., Wong, A., Melander, S., Gibson, R., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02808-3 · Cited by 181
Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease
Tabar, V., Sarva, H., Lozano, A. M., Fasano, A., Kalia, S. K., Yu, K. K. H., Brennan, C., Ma, Y., Peng, S., Eidelberg, D., et al. (2025) · Nature · doi:10.1038/s41586-025-08845-y · Cited by 181
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
“Trials have been conducted for other outcomes, such as breast cancer and neurodegenerative disorders [35 – 37].”
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
“In Parkinson’s disease, phase II trials have shown that GLP-1 RAs such as exenatide and lixisenatide improve motor activity compared to placebo, 53,54 and liraglutide has shown improvements in non-motor symptoms, mobility, and quality of life.”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“In real-world practice, the efficacy for weight reduction is often lower: for example, about 8 % for individuals with diabetes and 11 % for individuals without diabetes at”
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update
McFarthing, K., Buff, S., Rafaloff, G., Pitzer, K., Fiske, B. K., Navangul, A., Beissert, K., Pilcicka, A., Fuest, R., Wyse, R. K. H., et al. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240272 · Cited by 170
Self-citationNauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
α-Synuclein pathology as a target in neurodegenerative diseases
Park, H.-J., Kam, T., Dawson, V. L., & Dawson, T. M. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01043-w · Cited by 125
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
“While these benefits for neurodegeneration may involve antiinflammatory actions, direct attribution to such effects remains to be conclusively demonstrated.”
Hölscher, C. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109952 · Cited by 108
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 112
De Giorgi, R., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A. I., Koychev, I., Upthegrove, R., Solmi, M., McCutcheon, R., Pillinger, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00390-x · Cited by 77
“Only a minority of studies, that is, four in Parkinson’s disease 52–55 , five in substance-use disorders 111,113,115–117 , one in psychotic disorders 144 and two in mood disorders 178,179,182 , assessed the cognitive and mental health effects of GLP-1RAs in non-diabetic, non-obese populations.”
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Hong, C.-T., Chen, J.-H., & Hu, C.-J. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01090-x · Cited by 78
“Following a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 2.9 points higher in the placebo group, under-scoring the potential benefits of lixisenatide in early PD [100].”
MethodInfluentialLakhani, M., Kwan, A. T. H., Mihalache, A., Popovic, M. M., Nanji, K., Xie, J. S., Feo, A., Rabinovitch, D., Shor, R., Sadda, S., et al. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.05.007 · Cited by 70
Multiple system atrophy: advances in pathophysiology, diagnosis, and treatment
Krismer, F., Fanciulli, A., Meissner, W. G., Coon, E. A., & Wenning, G. K. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00396-x · Cited by 73
“Furthermore, experimental studies and clinical data from related synucleinopathies 92–95 suggest that the Abelson tyrosine kinase and GLP-1 receptor agonists are promising therapeutic targets for multiple system atrophy, and these therapies are currently being tested in early clinical trials.”
Self-citationThe expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
West, J., Li, M., Wong, S., Le, G. H., Teopiz, K. M., Valentino, K., Dri, C. E., & McIntyre, R. S. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00724-y · Cited by 72
“A phase 2, double-blind, randomized, placebo-controlled trial investigated the effects of lixi-senatide, a GLP-1RA, on the progression of motor disability in early PD [30].”
InfluentialOld, V. J., Davies, M. J., Papamargaritis, D., Choudhary, P., & Watson, E. L. (2025) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13677 · Cited by 55
Allan, K. C., Joo, J. H., Kim, S., Shaia, J., Kaelber, D. C., Singh, R., Talcott, K. E., & Rachitskaya, A. V. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.01.016 · Cited by 54
Ebrahimi, P., Batlle, J. C., Ayati, A., Maqsood, M. H., Long, C., Tarabanis, C., McGowan, N., Liebers, D. T., Laynor, G., Hosseini, K., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0091 · Cited by 51
The liver–brain axis in metabolic dysfunction-associated steatotic liver disease
Mikkelsen, A. C. D., Kjærgaard, K., Schapira, A. H. V., Mookerjee, R. P., & Thomsen, K. L. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00320-0 · Cited by 67
Hurtado, I., Robles, C., Peiró, S., García-Sempere, A., & Sanfélix-Gimeno, G. (2024) · Diabetologia · doi:10.1007/s00125-024-06243-z · Cited by 45
Parkinson's disease and glucose metabolism impairment
Chen, L., Wang, C., Qin, L., & Zhang, H. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00467-8 · Cited by 57
Tirzepatide for overweight and obesity management
Hamza, M., Papamargaritis, D., & Davies, M. J. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436595 · Cited by 43
“Early-phase clinical trials indicate less progression of motor disability with GLP-1 RAs in Parkinson’s disease, and further studies show reduced incidence of cognitive impairment and dementia in people with T2D [96–98].”
Structural pharmacology and mechanisms of GLP-1R signaling
Zhou, Q., Zhao, F., Zhang, Y., Yang, D., & Wang, M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.03.003 · Cited by 52
Current therapeutic strategies in Parkinson’s disease: Future perspectives
Kim, T. Y., & Lee, B. D. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100274 · Cited by 59
Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity
Lin, H.-T., Tsai, Y.-F., Liao, P.-L., & Wei, J. C.-C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.21016 · Cited by 43
Tang, H., Lu, Y., Okun, M. S., Donahoo, W. T., Ramirez‐Zamora, A., Wang, F., Huang, Y., Armstrong, M. J., Svensson, M., Virnig, B. A., et al. (2024) · Movement Disorders · doi:10.1002/mds.29992 · Cited by 47
“34 Our observation of a signi fi cantly lower risk of PD in GLP-1RA users than in DPP4i users aligns with the enhanced ability of GLP-1RAs to activate GLP-1 receptors, surpassing the effects achieved through increasing endogenous GLP-1 levels with DPP4i.”
Neuroprotective effects of GLP-1 class drugs in Parkinson’s disease
Lv, D., Feng, P., Guan, X., Liu, Z., Li, D., Xue, C., Bai, B., & Hölscher, C. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1462240 · Cited by 49
Enteroendocrine cells: the gatekeepers of microbiome-gut-brain communication
Grundeken, E., & Aidy, S. E. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00810-x · Cited by 55
“Treatedgroupsexhibitedreducedmotordisability progression 125 or evenimprovement 126,127 compared to controls.”
From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics
Roy, A., Dawson, V. L., & Dawson, T. M. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00712 · Cited by 47
“Lixisenatide showed disease-modifying effects in the LIXIPARK trial by stabilizing motor symptoms in early PD [36]; however, additional studies are required to confirm these findings.”
InfluentialLi, Z., Lin, C., Cai, X., Lv, F., Yang, W., & Ji, L. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01645-y · Cited by 55
“Recently, GLP-1RA was demonstrated effective in early Parkinson’s disease, which indicated its protective impact on neurodegenerative disease [22].”
Advances in GLP-1 receptor agonists for pain treatment and their future potential
He, Y., Xu, B., Zhang, M., Chen, D., Wu, S., Gao, J., Liu, Y., Zhang, Z., Kuang, J., & Fang, Q. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-01979-4 · Cited by 46
The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
Menozzi, E., Schapira, A. H. V., & Borghammer, P. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70029 · Cited by 46
“126 129 In conclusion, although the pathogenic role of EECs in initiating enteric α -synuclein pathology and the pathophysiological role of altered GLP-1 responses in PD remain controversial, the dysfunction of the enteroendocrine system, possibly via alterations of the gut microbiome, represents…”
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Giorgi, R. D., Ghenciulescu, A., Yotter, C. N., Taquet, M., & Koychev, I. G. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-335593 · Cited by 48
“[Marx et al ; 82 ] Further research should plan to evaluate risks of long-term use with considerations to age, comorbidities and impact of fluctuating mental capacity that increases the risk of self-harm.”
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 54
“Clinical investigations have yielded mixed results, with the LixiPark trial demonstrating potential disease-modifying effects in patients with early Parkinson’s disease, showing slower motor symptom progression compared to the placebo group [115].”
The gut–brain axis in early Parkinson’s disease: from prodrome to prevention
Oliver, P. J., Civitelli, L., & Hu, M. T. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13138-5 · Cited by 42
Suárez, P. R., del Campo, N., Bénatru, I., Moreau, C., Desjardins, C., Sánchez‐Ferro, Á., & Fabbri, M. (2024) · Movement Disorders · doi:10.1002/mds.30056 · Cited by 46
Self-citationPathogenesis of Parkinson’s Disease
Xiao, B., Zhou, Z., Chao, Y., & Tan, E.-K. (2025) · Neurologic Clinics · doi:10.1016/j.ncl.2024.12.003 · Cited by 76
Newer glucose‐lowering drugs reduce the risk of late‐onset seizure and epilepsy: A meta‐analysis
Sindhu, U., Sharma, A., Zawar, I., & Punia, V. (2024) · Epilepsia Open · doi:10.1002/epi4.13091 · Cited by 36
Evolving Landscape of Parkinson’s Disease Research: Challenges and Perspectives
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2025) · ACS Omega · doi:10.1021/acsomega.4c09114 · Cited by 45
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 41
“An analysis of prospective data gathered during the CVOTs in T2DM found that the risk of new-onset dementia with liraglutide or semaglutide was more than halved over 4 years, and lixisenatide has been reported to slow motor deterioration in Parkinson ’ s disease [90].”
Genetics of Parkinson's Disease: From Causes to Treatment
Westenberger, A., Brüggemann, N., & Klein, C. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041774 · Cited by 42
Dopamine Pharmacodynamics: New Insights
Lauretani, F., Giallauria, F., Testa, C., Zinni, C., Lorenzi, B., Zucchini, I., Salvi, M., Napoli, R., & Maggio, M. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105293 · Cited by 43
“A very recent trial published on April 3 demonstrates that the action of Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, is somehow neuroprotective in patients with early onset of Parkinson’s disease [120].”
BackgroundMcIntyre, R. S., Rasgon, N., Goldberg, J. F., Wong, S., Le, G. H., Mansur, R. B., Rosenblat, J. D., Teopiz, K. M., & Stahl, S. M. (2025) · CNS Spectrums · doi:10.1017/s1092852925000124 · Cited by 40
On the causes of obesity and its treatment: The end of the beginning
Friedman, J. M. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.026 · Cited by 34
Zhang, P., Mao, C., Sun, A., Yang, Y., Hou, Y., Fu, Z., Tousi, B., Leverenz, J. B., Pieper, A. A., Luo, Y., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70639 · Cited by 33
“…has shown a beneficial effect on motor ability in two phase 2 trials and is currently being assessed in a phase 3 trial, 26–28 lixisenatide also showed beneficial effect on motor ability in a phase 2 trial, 29 and liraglutide and semaglu-tide are currently being evaluated in phase 2 trials.”
The promise of GLP-1 receptor agonists for neurodegenerative diseases
Athauda, D. S., Greig, N. H., Meissner, W. G., Foltynie, T., & Gandhi, S. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194745 · Cited by 43
“More encouragingly, a phase II randomized controlled trial (RCT) of lixisenatide ( n = 156) reported slower motor decline over 12 months (159), while liraglutide improved nonmotor symptoms but not motor endpoints (160).”
Self-citationGLP‐1 receptor agonists for Parkinson's disease: An updated meta-analysis
de Albuquerque, M. B., Nunes, L. E. D. B., Maldonado, J. V. D. O., Ferreira, D. G. M., Margato, M. M., Rabelo, L. V., Valênça, M. M., & Cordeiro, L. H. O. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107220 · Cited by 30
Tseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 36
GLP-1, Parkinson’s Disease, and Neuroprotection
Standaert, D. G. (2024) · New England Journal of Medicine · doi:10.1056/nejme2401743 · Cited by 27
α-Synuclein pathology and mitochondrial dysfunction: Toxic partners in Parkinson's disease
Mingo, Y. B., Galvis, M. L. E., & Henderson, M. X. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106889 · Cited by 31
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
“…period of 39.8 months, semaglutide demonstrated superiority over placebo in reducing the composite endpoint of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among overweight or obese patients with established cardiovascular disease, but without diabetes.”
InfluentialGlucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 35
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 41
Body-wide multi-omic counteraction of aging with GLP-1R agonism
Huang, J., Kwok, A. J., Li, J. C. Y., Chiu, C. L. H., Ip, B. Y. M., Tung, L. Y., Chan, R. C. H., Chan, D. T.-M., Wang, Z., Zheng, X., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.10.014 · Cited by 37
Kopp, K. O., Li, Y., Glotfelty, E. J., Tweedie, D., & Greig, N. H. (2024) · Biomolecules · doi:10.3390/biom14070872 · Cited by 27
“…been completed, with encouraging results comprising improved off-medication motor scores, motor ability, and cognitive function in PD patients [40–43], as well as improved brain glucose metabolism [44] and reduced amyloid-β 1-42 concentration in neuronal-derived extracellular vesicles [45] in…”
ResultThe role of macrophage plasticity in neurodegenerative diseases
Ma, H., Zhu, M., Chen, M., Li, X., & Feng, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00624-7 · Cited by 25
“A phase II clinical trial showed that Lixisenatide (lisenatide, developed by Sanofi), a GLP-1 receptor agonist for the treatment of diabetes, could slow down the progress of Parkinson’s disease related dyskinesia after 12 months of treatment [210].”
BackgroundQin, H., Yu, J., Yu, H., Zhou, C., Yuan, D., Wang, Z., Zhu, Z., Wei, G., Ou, P., Li, Z., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.01.008 · Cited by 30
Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease
Tanvir, A., Jo, J., & Park, S. M. (2024) · Cells · doi:10.3390/cells13221876 · Cited by 69
“A recent phase 2 trial reported that lixisenatide reduced motor disability progression, albeit with some gastrointestinal side effects [157].”
Stone, C. R., Harris, D. D., Broadwin, M., Kanuparthy, M., Nho, J.-W., Yalamanchili, K., Hamze, J., Abid, M. R., & Sellke, F. W. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321850 · Cited by 26
Szegő, É. M., Höfs, L., Antoniou, A., Dinter, E., Bernhardt, N. R., Schneider, A., Monte, D. A. D., & Falkenburger, B. H. (2025) · Nature Communications · doi:10.1038/s41467-025-59249-5 · Cited by 31
“In contrast, anti-diabetic medication with the glucagon-like peptide-1 receptor agonist lixisenatide reduces motor progression over 12 months in patients with PD 67 .”
Deng, S., Chen, Z., & Shi, Y. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01486-8 · Cited by 30
Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?
Kopp, K. O., Glotfelty, E. J., Li, Y., Lahiri, D. K., & Greig, N. H. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102343 · Cited by 24
Prospects for Disease Slowing in Parkinson Disease
Menozzi, E., & Schapira, A. H. V. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022124-033653 · Cited by 27
Hölscher, C. (2025) · CNS Drugs · doi:10.1007/s40263-025-01226-z · Cited by 30
“In addition, the drug group took less l -DOPA at the end of the trial compared with controls [191].”
Shchendrygina, A., Rakisheva, A., Giverts, I., Rustamova, Y., & Soloveva, A. E. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.05 · Cited by 24
“60–62 In addition, published reports suggest efficacy of GLP-1 RAs against weight gain related to the use of antipsychotic medication that may affect a patient’s feelings.”
BackgroundStockmann, O., Ye, L., Greten, S., Chemodanow, D., Wegner, F., & Klietz, M. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02882-7 · Cited by 22
Aerobic exercise-induced changes in fluid biomarkers in Parkinson’s disease
Luthra, N., Mehta, N., Munoz, M. J., Fantuzzi, G., Lamotte, G. J., Haus, J. M., McFarland, N. R., Tansey, M. G., González-Latapí, P., Caraveo, G., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01042-8 · Cited by 28
“Severalantidiabetic drugs,i.e.exenatideandlixisenatide,arebeingexploredaspotentialdisease-modifyingagentsforPD 273,274 .”
Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
Myerson, M. L., & Paparodis, R. D. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2487 · Cited by 20
“61”
Sun, Y., Zhou, Q., Onzere, L. E., Dian, Y., Yu, M., Li, D., Zeng, F., Lei, S., & Deng, G. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103186 · Cited by 21
Incretin-based therapeutics for the treatment of neurodegenerative diseases
Vear, A., Heneka, M. T., & Clemmensen, C. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01263-4 · Cited by 26
“Two double-blind, randomized, placebo-controlled phase II trials testing 12 months of treatment with liraglutide (NCT02953665) or lixisenatide (LixiPark NCT03439943) also showed slowed worsening of motor symptoms 165,166 .”
Helal, M. M., AbouShawareb, H., Abbas, O., Haddad, R., Zain, Y. E., Osman, A. S. A., & Hassan, A. K. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01888-1 · Cited by 23
“Another factor to consider when interpreting our results with caution is the inconsistency in the endpoints across the included studies, with follow-up periods ranging from 44 to 60 weeks [27–31].”
InfluentialDopaminergic signalling in gastrointestinal health and disease
Pasricha, T. S., & Kulkarni, S. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01112-5 · Cited by 21
“GLP1 agonists have been shown to be centrally neuroprotective, reducing dopaminergic neuronal loss in the brain in Parkinson disease models 117,118 and, in a major human clinical trial, to slow disease progression 118,119 .”
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 26
Multi-faceted roles of β-arrestins in G protein-coupled receptor endocytosis
Liu, J., Li, X., Ravier, M. A., Eshak, F., Acher, F., Lamy, A., Cimadevila, M., Drube, J., Hoffmann, C., Inoue, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67156-y · Cited by 25
Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease
Fabbri, M., Rascol, O., Foltynie, T., Carroll, C., Postuma, R. B., Porcher, R., & Corvol, J. (2024) · Movement Disorders · doi:10.1002/mds.29899 · Cited by 24
Self-citationMcIntyre, R. S., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2430306 · Cited by 22
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Metabolic Dysfunction in Parkinson’s Disease: Unraveling the Glucose–Lipid Connection
Sian‐Hülsmann, J., Riederer, P. F., & Michel, T. M. (2024) · Biomedicines · doi:10.3390/biomedicines12122841 · Cited by 20
“Lixisenatide, a glucagon-like peptide agonist used in treating Diabetes Mellitus Type 2 and obesity, has been shown to have neuroprotective attributes in the PD mouse model [97].”
Neural Influences on Tumor Progression Within the Central Nervous System
Lv, W., & Wang, Y. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70097 · Cited by 18
“Concurrently, the administration of neuroprotective agents, which do not contribute to tumor progression, is imperative for safeguarding healthy brain tissues [243, 244].”
BackgroundDisease-Modifying Therapies in Parkinson’s Disease
Fabbri, M., Corvol, J., & Rascol, O. (2025) · Neurologic Clinics · doi:10.1016/j.ncl.2024.12.009 · Cited by 18
Self-citationGao, X., Ding, J.-E., Xie, J., & Xu, H. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01499-6 · Cited by 19
Shafqat, A., Masters, M. C., Tripathi, U., Tchkonia, T., Kirkland, J. L., & Hashmi, S. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102400 · Cited by 15
Clinical Trial Highlights: Anti-Inflammatory and Immunomodulatory Agents
Patel, B., Greenland, J. C., & Williams‐Gray, C. H. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240353 · Cited by 24
Messak, M., Abdelmageed, A., Senbel, A. A., Khattab, Y. A., Mandour, Y., Shaker, O., Rehan, A. H., Oransa, S., Nasr, M., Shabeeb, A. E., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03932-3 · Cited by 20
“More studies have been published since then with conflicting results regarding the progression of the motor disability of PD patients (McGarry et al. 2024; Meissner et al. 2024) and therefore an update systematic review and meta-analysis is needed.”
InfluentialFrom pathogenesis to treatment: the emerging role of ferroptosis in Parkinson’s disease
Tu, R., Han, Z., Zhang, H., Jia, X., Sun, T., Liu, H., Li, J., Tang, M., & Wang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1709561 · Cited by 17
Sabbagh, M. N., Cummings, J. L., Ballard, C. G., van der Flier, W. M., Heneka, M. T., Holst, J. J., Knudsen, L. B., Salloway, S., Tansey, M. G., & Drucker, D. J. (2025) · Nature Aging · doi:10.1038/s43587-025-01029-3 · Cited by 17
“Thus, GLP-1RAs are unlikely to emerge as a treatment for ALS.”
Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus
Dou, X., Zhao, L., Li, J., & Jiang, Y. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1537898 · Cited by 19
NFκB1: a common biomarker linking Alzheimer's and Parkinson's disease pathology
Cunningham, A., Barrett, E., Risch, S., Lee, P. H. U., Lee, C. M., Moghekar, A., Patra, P., & Shim, J. W. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1589857 · Cited by 15
Incretins and the cardiovascular system: bridging digestion with metabolism
Avogaro, A., & Fadini, G. P. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00166-4 · Cited by 21
Gandhi, A., & Parhizgar, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1708565 · Cited by 18
Zhang, B., Song, C., Tang, X., Tian, M., Liu, Y., Yan, Z., Duan, R., & Liu, Y. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1422746 · Cited by 16
“A recent study published in the New England Journal of Medicine demonstrated the signi fi cant effect of the GLP-1 class drug liraglutide in slowing motor impairments in early-stage Parkinson ’ s disease patients during a 12-month treatment period (Meissner et al., 2024).”
BackgroundDesigning the First Trials for Parkinson’s Prevention
Crotty, G. F., Ayer, S. J., & Schwarzschild, M. A. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240164 · Cited by 13
Metadata
- Authors
- Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J.-L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., Carrière, N., Catala, H., Charif, M., Colin, O., Corvol, J.-C., Damier, P., Dellapina, E., Devos, D., Drapier, S., Fabbri, M., Ferrier, V., Foubert-Samier, A., Frismand-Kryloff, S., Geny, C., Georget, A., Germain, C., Grimaldi, S., Hardy, C., Hopes, L., Krystkowiak, P., Laurens, B., Lefaucheur, R., Mariani, L.-L., Marques, A., Marse, C., Ory-Magne, F., Rigalleau, V., Salhi, H., Saubion, A., Stott, S. R. W., Thalamas, C., Thiriez, C., Tir, M., Wyse, R. K., Benard, A., & Rascol, O.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- French Clinical Research Network for Parkinson’s Disease and Movement Disorders (NS-Park/F-CRIN), France
- Université Côte d'Azur (FR)
- Inserm (FR)
- Clinical Investigation Center CIC1436 and Departments of Clinical Pharmacology and Neurosciences, Centre Expert Parkinson, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse, France
- Université de Bordeaux (FR)
- French Clinical Research Infrastructure Network (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Cure Parkinson’s, London, UK
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Service d’Information Médicale, Clinical Epidemiology Unit (USMR), CHU Bordeaux, F-33000 Bordeaux, France
- ORCID
- Meissner, Wassilios G.
- Maltête, David
- Derkinderen, Pascal
- Houéto, Jean-Luc
- Anheim, Mathieu
- Boraud, Thomas
- Carrière, Nicolas
- Colin, Olivier
- Corvol, Jean-Christophe
- Damier, Philippe
- Dellapina, Estelle
- Devos, David
- Drapier, Sophie
- Fabbri, Margherita
- Grimaldi, Stéphane
- Hopes, Lucie
- Laurens, Brice
- Lefaucheur, Romain
- Mariani, Louise-Laure
- Rigalleau, Vincent
- Stott, Simon R. W.
- Thalamas, Claire
- Thiriez, Claire
- Tir, Mélissa
- Wyse, Richard K.
- Rascol, Olivier
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-04-04
- Volume
- 390
- Issue
- 13
- Pages
- 1176-1185
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4393852482
- Cited by
- 369
- References
- 30
- Citations by year
- 2026: 125 · 2025: 160 · 2024: 83
- FWCI
- 97.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
- Funders
- Cure Parkinson’s
- French Ministry of Health - PHRC-N
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- lixisenatide, Parkinson's disease, GLP-1 receptor agonists, early-stage Parkinson's disease, MDS-UPDRS III, levodopa equivalent daily dose, nausea, neuroprotection, off-medication state, washout period, subcutaneous administration, anti-inflammatory therapy, neurodegeneration, neuroinflammation
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Motor Disorders, Glucagon-Like Peptide-1 Receptor Agonists, Antiparkinson Agents, Double-Blind Method, Persons with Disabilities, Humans, Injections, Subcutaneous, Parkinson Disease, Peptides, Treatment Outcome, Disease Progression, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.